API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The FDA approved COSELA™ (trilaciclib) as the first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression.
Lead Product(s): Trilaciclib,Irinotecan Hydrochloride,Oxaliplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: G1 Therapeutics, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
Autogene cevumeran (RO7198457) is a messenger RNA (mRNA)-based personalized cancer vaccine, which is being evaluated in combination with atezolizumab for the treatment of resected pancreatic ductal adenocarcinoma.
Lead Product(s): Autogene Cevumeran,Atezolizumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: RO7198457
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
Astellas' Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for patients with HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: VYLOY
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
IMAB362 (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to claudin 18.2 (CLDN18.2). It is being evaluated in phase 3 studies for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Zolbetuximab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
AK104 (cadonilimab) is a bispecific antibody that targets both PD-1 & CTLA-4. It is under phase 3 clinical development in combination with chemotherapy for the treatment of unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Cadonilimab,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: AK104
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
BNT122 is a mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran, which is investigated for the treatment of resected pancreatic ductal adenocarcinoma.
Lead Product(s): Autogene Cevumeran,Atezolizumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: BNT122
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic.
Lead Product(s): Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allarity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 31, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
TST001 (osemitamab) is a high affinity humanized anti-Claudin18.2 mAb with enhanced ADCC and CDC activities and potent anti-tumor activities in tumor xenograft models. It is being investigated in combination with CAPOX for gastric/gastro-esophageal junction cancer.
Lead Product(s): Osemitamab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
BGB-A317 (tislelizumab) is a humanized IgG4 anti-PD-1 mAb, designed to minimize binding to Fcγ receptors on macrophages, helping immune cells to detect and fight tumors. It is being investigated for Advanced gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Tislelizumab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka’s platform of molecules. The combination of two cytokines increases potency and reduces toxicity while targeting system also improves the drug's efficacy, safety, and manufacturability.
Lead Product(s): DK210,Paclitaxel,Oxaliplatin
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka’s platform of molecules. The combination of two cytokines increases potency and reduces toxicity while targeting system also improves the drug's efficacy, safety, and manufacturability.
Lead Product(s): DK210,Paclitaxel,Oxaliplatin
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Onivyde (irinotecan) is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die.
Lead Product(s): Irinotecan Hydrochloride,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
ZW25 (zanidatamab) is an investigational bispecific antibody, based on Zymeworks' Azymetric™ platform, that simultaneously bind two non-overlapping epitopes of HER2, which encourages antitumor activity in patients. It is being investigated for solid tumors that express HER2.
Lead Product(s): Zanidatamab,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Zymeworks
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
IMAB362 (Zolbetuximab), is an investigational first-in-class Claudin-18.2 targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma.
Lead Product(s): Zolbetuximab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
In AGENT study, patients with non-resectable mCRC treated with arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab did not achieve a statistically significant overall response rate of ≥ 10% as compared to patients treated with the standard of care.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Modufolin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2022
Details:
IMAB362 (zolbetuximab) is an investigational first-in-class mAB targeting Claudin 18.2 (CLDN18.2), for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Efti (IMP321) is Immutep’s proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell (APC) activator for the treatment of cancer, capitalising on LAG-3’s unique characteristics to stimulate both innate and adaptive immunity.
Lead Product(s): Eftilagimod Alpha,Oxaliplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that alters the unfolded protein response (UPR) through selective GRP78 inhibition and induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
In vivo (in living organisms), TUKYSA (tucatinib) inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either medicine alone.
Lead Product(s): Tucatinib,Trastuzumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: Tuksya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
TST001 (Osemitamab) is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("ADCC") and complement-dependent cytotoxicity ("CDC") activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Progression-free survival (PFS) was approximately 12.8 months for the arfolitixorin arm and 11.6 months for the control arm, with a P-value of 0.76. Data for this endpoint is not final but it is not deemed to change significantly moving forward.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Modufolin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).
Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: IPH4102
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
TST001 is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
At a median duration of follow-up of 20.7 months, results of MOUNTAINEER trial showed a 38.1% cORR per blinded independent central review in HER2-positive patients who were assigned to receive Tuksya (tucatinib) in combination with trastuzumab.
Lead Product(s): Tucatinib,Trastuzumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: Tuksya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2022
Details:
CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Sintilimab, marketed as TYVYT in China, is a PD-1 immunoglobulin G4 monoclonal antibody, is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on surface of T-cells, blocks PD-L1 pathway, and reactivates T-cells to kill cancer cells.
Lead Product(s): Sintilimab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
sBLA is supported by data from an interim analysis from the global RATIONALE 305 trial of BGB-A317 (tislelizumab) versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic G/GEJ adenocarcinoma.
Lead Product(s): Tislelizumab,Cisplatin,Oxaliplatin
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Sudy published in PLOS ONE titled, Evidence for novel, effective approach to targeting carcinoma catabolism exploiting anti-cancer mitochondrial drug, CPI-613 multi-target, tumor-preferential inhibition of mitochondrial TCA cycle by first-in-class drug, devimistat.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
CEND-1 is an investigational drug that modifies the tumor microenvironment. It is targeted to tumor vasculature by its affinity for alpha-v integrins that are selectively expressed in tumor, but not healthy tissue vasculature.
Lead Product(s): CEND-1,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Lisata Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
TST001 is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Epizyme
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
CEND-1 is a cyclic peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment, which binds to a second receptor, called neuropilin-1, to activate a novel uptake pathway.
Lead Product(s): CEND-1,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Lisata Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Zymeworks' global Phase 3 study, HERIZON-GEA-01, which is investigating ZW25 (zanidatamab) in combination with chemotherapy plus or minus tislelizumab for first-line treatment of locally advanced, unresectable, or metastatic HER2-positive gastroesophageal adenocarcinoma.
Lead Product(s): Zanidatamab,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
TST001 is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Nivolumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
Zanidatamab, a HER2-targeted bispecific antibody, in combination with chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GJEC): Preliminary results from a Phase 1b/2 study.
Lead Product(s): Zanidatamab,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Results showed that the use of trilaciclib prior to chemotherapy was associated with a 50% reduction in the percent of patients with grade ≥ 3 myelosuppressive hematologic adverse events in at least one blood cell lineage and 74% reduction in the percent.
Lead Product(s): Trilaciclib,Irinotecan Hydrochloride,Oxaliplatin
Therapeutic Area: Oncology Product Name: G1T28
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
OxaliTEX, is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer, has received a notice of allowance for patent in Korea adds further global protection.
Lead Product(s): Oxaliplatin,Texaphryn
Therapeutic Area: Oncology Product Name: OxaliTEX
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
The CHMP’s recommendation was based on results from Phase 2 KEYNOTE-158 trial as well as results from Phase 2 KEYNOTE-164 trial, both of which supported U.S.FDA accelerated approval of KEYTRUDA as cancer treatment approved based on a biomarker in MSI-H or dMMR solid tumors.
Lead Product(s): Pembrolizumab,Fluoropyrimidine,Oxaliplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
The Data Review Committee has declared the 900 µg/kg mitazalimab, an agonistic or stimulatory antibody that targets CD40 dose to be safe and recommended that the dosing level should be continued for the Phase II study.
Lead Product(s): Mitazalimab,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
Preclinical experiments have repeatedly shown that BOLD-100 improves outcomes in combination with a wide range of existing anti-cancer therapies, with particular synergy evident in drug-resistant cell lines.
Lead Product(s): BOLD-100,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hana Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 13, 2022
Details:
Arfox (Arfolitixorin), is the first and only immediately active folate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2021
Details:
As the first and only pure form of the folate ([6R]-MTHF) that increases 5FU-cytotoxicity, arfolitixorin is currently being evaluated in the global pivotal Phase III AGENT study used for treatment of patients with metastatic colorectal cancer (mCRC).
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021